Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
about
Predictive value of phosphorylated mammalian target of rapamycin for disease-free survival in breast cancer patients receiving neoadjuvant chemotherapy.EIF4EBP1 overexpression is associated with poor survival and disease progression in patients with hepatocellular carcinomaPhospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinomaKnockdown of eukaryotic translation initiation factor 4E suppresses cell growth and invasion, and induces apoptosis and cell cycle arrest in a human lung adenocarcinoma cell line.Overexpression of eIF4E in colorectal cancer patients is associated with liver metastasisPrognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma.Eukaryotic translation initiation factors and cancer.The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy.A novel function of cIAP1 as a mediator of CHIP-driven eIF4E regulation.Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy.RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.Beyond molecular tumor heterogeneity: protein synthesis takes control.Increased expression of MNK1b, the spliced isoform of MNK1, predicts poor prognosis and is associated with triple-negative breast cancer.Expression of 4E-BP1 and phospho-4E-BP1 correlates with the prognosis of patients with clear cell renal carcinoma.
P2860
Q34427536-9115A3E0-02BC-4824-B2F1-D74FF6016EA2Q35058443-F537C0EC-6AFC-436F-859A-835833BAA0ABQ36250674-6280E362-6FF7-48F4-8D56-BD3F1E418506Q38543715-A115E1C6-4F28-441F-BF32-A12E70374293Q38628054-7740B5AF-EDA2-40E8-9886-45CCA8666B8EQ38747860-63FBA8BA-3D5D-4518-8DFD-E7DDF1CEF636Q39400409-792E4542-77FC-46EA-BF24-6A08BA902938Q41036251-5860CD90-9BFB-4F87-AF00-83F29DC90627Q41549983-7BCCAD6D-A6CB-478F-A920-4B6A141256DFQ42754623-20A2A165-7B4E-4597-98A5-F6D95A2C61FEQ48123819-BBD9A4C2-248D-40D4-B668-745E2125C0EFQ49789362-C6304CF9-A100-4867-B5B5-EC2F9A8E1C71Q54796100-78D8D79A-F78E-4303-959D-9929799D9818Q55294408-D4CB116D-90D0-4A0C-8B43-1438212DCA59
P2860
Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Eukaryotic translation initiat ...... ycline chemotherapy treatment.
@en
Eukaryotic translation initiation factor 4E
@nl
type
label
Eukaryotic translation initiat ...... ycline chemotherapy treatment.
@en
Eukaryotic translation initiation factor 4E
@nl
prefLabel
Eukaryotic translation initiat ...... ycline chemotherapy treatment.
@en
Eukaryotic translation initiation factor 4E
@nl
P2093
P2860
P50
P1476
Eukaryotic translation initiat ...... ycline chemotherapy treatment.
@en
P2093
Kristiina Aittomäki
Olli Carpén
Päivi Heikkilä
Rainer Fagerholm
Taina Korpela
P2860
P2888
P356
10.1007/S10549-013-2671-2
P407
P577
2013-08-24T00:00:00Z